Next Article in Journal
Efficient Delivery and Replication of Oncolytic Virus for Successful Treatment of Head and Neck Cancer
Next Article in Special Issue
Dietary Mg2+ Intake and the Na+/Mg2+ Exchanger SLC41A1 Influence Components of Mitochondrial Energetics in Murine Cardiomyocytes
Previous Article in Journal
In Situ Gelling Systems Using Pluronic F127 Enhance Corneal Permeability of Indomethacin Nanocrystals
Previous Article in Special Issue
Quantification of Iron Release from Native Ferritin and Magnetoferritin Induced by Vitamins B2 and C
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Review of the Action of Magnesium on Several Processes Involved in the Modulation of Hematopoiesis

by
Fabiana da Silva Lima
1 and
Ricardo Ambrósio Fock
2,*
1
Department of Food and Experimental Nutrition, School of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508-000, Brazil
2
Laboratory of Experimental Hematology, Department of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, Avenida Lineu Prestes, 580-Bloco 17, São Paulo 05508-000, Brazil
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(19), 7084; https://doi.org/10.3390/ijms21197084
Submission received: 28 August 2020 / Revised: 17 September 2020 / Accepted: 22 September 2020 / Published: 25 September 2020

Abstract

:
Magnesium (Mg2+) is an essential mineral for the functioning and maintenance of the body. Disturbances in Mg2+ intracellular homeostasis result in cell-membrane modification, an increase in oxidative stress, alteration in the proliferation mechanism, differentiation, and apoptosis. Mg2+ deficiency often results in inflammation, with activation of inflammatory pathways and increased production of proinflammatory cytokines by immune cells. Immune cells and others that make up the blood system are from hematopoietic tissue in the bone marrow. The hematopoietic tissue is a tissue with high indices of renovation, and Mg2+ has a pivotal role in the cell replication process, as well as DNA and RNA synthesis. However, the impact of the intra- and extracellular disturbance of Mg2+ homeostasis on the hematopoietic tissue is little explored. This review deals specifically with the physiological requirements of Mg2+ on hematopoiesis, showing various studies related to the physiological requirements and the effects of deficiency or excess of this mineral on the hematopoiesis regulation, as well as on the specific process of erythropoiesis, granulopoiesis, lymphopoiesis, and thrombopoiesis. The literature selected includes studies in vitro, in animal models, and in humans, giving details about the impact that alterations of Mg2+ homeostasis can have on hematopoietic cells and hematopoietic tissue.

1. Introduction

In recent years, researches have shown that alterations in Mg2+ homeostasis, a result of the inadequacy of consumption or the moderate or severe deficiency of this mineral, in animal or in vitro and human models, can result in inflammation. Mg2+ deficiency frequently results in nuclear factor kappa B (NF-ĸB) pathway activation in immune cells with increased production of proinflammatory cytokines and acute-phase proteins such as interleukin (IL)-6, tumor necrosis factor alpha (TNF-α), and C-reactive protein (CRP), and it is related to the development of chronic diseases [1]. The number of experimental studies that demonstrated how Mg2+ deficiency alters the functioning of cells from hematopoietic origin are uncountable. These alterations include increased numbers of leukocytes in the peripheral blood, activation of cells such as neutrophils and macrophages, decreased antibody production, and the arrest of the cell cycle, thereby altering cell-cycle regulation and the activity of cyclins and cyclin-dependent kinases (CDKs) [2,3,4,5,6]. In lymphocytes, data indicate a role for magnesium in cell proliferation, also modulating the development of B cells and immunoglobulin production, as well as affecting functions of T cells [2,7,8]. In this context, much remains to be explored about the importance of intracellular Mg2+ homeostasis in cells of hematopoietic origin.
In addition to leukocytes, we and others have shown that Mg2+ is important for mechanisms of proliferation, differentiation, and immunomodulation of MSCs (mesenchymal stem cells), and these cells are relevant to both the immune system and the hematopoietic tissue due to its immunomodulatory properties and differentiation capacity in osteoblasts, adipocytes, and chondrocytes [9,10,11]. In vitro studies have shown that reduced Mg2+ concentration in the culture cell medium is able to decrease the expression of genes such as ALP (alkaline phosphatase), COL1 (Collagenase I) and RUNX2 (RUNX family transcription factor 2), during the differentiation of bone-marrow-derived MSCs into osteoblasts [12]. Osteoblasts are very important for hematopoietic tissue [13,14]. However, the impact of changes in Mg2+ homeostasis in osteoblasts on bone marrow and, consequently, on hematopoietic tissue is unknown.
Studies showing the effect of disturbances in Mg2+ homeostasis on the mechanisms of differentiation, proliferation, and maturation of hematopoietic cells in the bone marrow are rare, and there are few references in recent decades about this topic, whereby the majority of the results were obtained only in experimental models [15]. These studies demonstrated the impact of Mg2+ deficiency on peripheral blood cells [4,5] or on the lymphocyte maturation process, as well as on thrombopoiesis, with a focus on the transient receptor potential cation channel subfamily M member 7 (TRPM7) channel [16,17]. Several studies raised the importance of intracellular Mg2+ homeostasis via the TRPM7 channel, which in addition to being permeable to Mg2+, is also permeable to Ca2+ and Zn2+, relevant for processes such as growth, survival, differentiation, and cell migration [18,19,20,21,22,23]. However, the importance of TRPM7 in Mg2+ homeostasis has been questioned, especially in T cells, where TRPM7 deletion did not affect acute uptake or maintenance of total cellular Mg2+; this is because, in immune cells, Mg2+ may be taken up by magnesium transporter 1 (MagT1) [7]. Nevertheless, these processes are not entirely clear and remain need to be investigated.
Although the impact of alterations in Mg2+ homeostasis needs to be clarified, especially Mg2+ deficiency in bone marrow and hematopoiesis, many clues indicate that changes in Mg2+ concentrations may have profound impacts on hematopoietic tissue. In the last few decades, several studies pointed indirectly to this when they related the importance of Mg2+ for cell-cycle progress, cell differentiation, apoptosis, the balance between osteoblast and adipocytes, etc. [3,24,25,26,27,28,29,30]. In light of the above, our objective in this review is to discuss how changes in Mg2+ homeostasis could influence bone marrow and, consequently, the hematopoiesis process, and what mechanisms may be involved. Understanding how this micronutrient can influence the hematopoietic process is relevant to highlight the importance of this mineral in the complex physiology of blood cell production, providing insight into the roles of this mineral in the physiological process or even in some hematopoietic pathologies. Given the scarcity of data related to the impact of changes on Mg2+ homeostasis in hematopoietic tissue, we focused on publications that evaluated the importance of Mg2+ for various types of cells of hematopoietic origin and stromal cells, with the latter being fundamental for the maintenance of hematopoietic tissue. The main findings of this review are compiled in Table 1.
It is important to note that the literature has many mechanistic studies performed in vitro using hematopoietic or lineage cells cultivated in combination with a supraphysiological concentration of Mg2+ or even using reduced or absent Mg2+ concentrations, which is often incompatible with real life. Therefore, understanding how changes in Mg2+ homeostasis can influence hematopoietic cells in vivo is a challenge. Since, the serum Mg2+ does not reflect its intracellular content, serum Mg2+ levels below the reference range (commonly used to diagnose deficiency) reflect only severe deficiency of this mineral, whereas the effects of moderate deficiency may be discrete and clinically underestimated.

2. The Role of Mg2+ in Hematopoiesis

2.1. The Hematopoietic Microenvironment

Since the 1920s, a series of studies made it possible to understand the role of hematopoietic stem cells (HSCs) and hematopoiesis [57,58,59]. Together, several studies showed that hematopoiesis is a complex, dynamic, and continuous process, in which HSCs proliferate, differentiate, and aggregate in the myeloid or lymphoid lineages, giving rise to the different types of cells that make up the blood system [60,61,62,63]. These processes occur in the bone marrow of mammalian adults under normal conditions and are highly regulated such that the hematopoietic system supplies thousands of mature blood cells to the body daily. The hematopoietic cells perform many essential functions for the survival of the organism, such as oxygen supply, regulation of blood homeostasis, and control of adaptive and innate immunity [64,65]. In this way, the continuous production of many blood cell types requires a highly regulated yet highly responsive system. In 1978, one of the first reports was published that proposed a concept called “niche” in the bone marrow microenvironment, which is a complex multicellular network that provides molecular cues and physical interactions that are essential for the proliferation, self-renewal, differentiation, and migration of HSCs and progenitor cells [66].
The cellular constituents of the bone marrow microenvironment largely derive from a common progenitor of mesenchymal origin called mesenchymal stem cells (MSCs); these cells are rare hematopoiesis-supporting stromal cells that have self-renewal potential and the capacity to differentiate into bone, fat, and cartilage. Furthermore, it is postulated that MSCs are essential in the formation and control of hematopoietic niches, which include the osteoblastic, vascular, and perivascular niches [67]. These niches can modulate different aspects of the hematopoiesis process, having the important role of cell–cell interaction and contact for the medullary microenvironment, as well as the production of soluble factors (cytokines and growth factors) and formation of an extracellular matrix that forms the supporting parenchyma [66,68]. All these elements act in different ways for the homeostasis of HSCs, as well as for the differentiation process of HSCs and progenitor hematopoietic cells and the mobilization of mature cells into peripheral blood [69,70,71]. However, the initiating factors that determine the differentiation process of HSCs are not entirely clear, and it is unknown how changes in Mg2+ homeostasis can influence the bone marrow microenvironment. However, on the basis of studies that demonstrated the influence of this mineral on the cells that make up the medullary microenvironment, which are cells that support and maintain hematopoiesis, it is possible to infer that Mg2+ is very important for the homeostasis of this tissue, since it is an essential mineral for several cellular functions.

2.1.1. The Influence of Mg2+ in Mesenchymal Stem Cells, Osteoblasts, and Adipocytes

Among the cells that make up the stroma, bone marrow mesenchymal stem cells (BMSCs) play a central role in the bone marrow microenvironment due to their ability to differentiate into strains that are very important for the maintenance of hematopoietic tissue, such as osteoblasts and adipocytes. A balance in the differentiation between osteoblasts and adipocytes is extremely significant because adipocytes are a negative regulator of hematopoiesis and osteoblasts are promoters [14,72,73]. Alterations in Mg2+ homeostasis are implicated in changes in the differentiation process of MSCs; whereas their increase promotes osteoblastogenesis, Mg2+ deficiency appears to be detrimental to bone health [74,75]. In BMSCs from experimental models, an increase in Mg2+ concentration elevated the expression of RUNX2, OSTERIX, and OSTEOCALCIN genes, increased the levels of cyclin D1 and proliferating cell nuclear antigen (PCNA) proteins, and induced the activation of Notch signaling [31]. Studies with osteoblasts from animal models verified that 6 mM and 10 mM Mg2+ upregulated RUNX2, BMP2, ALP, OPN, and COL1 expression and increased the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway [32]. In addition to RUNX2 and ALP, researchers showed in hFOB1.19 human osteoblast cells that increased of Mg2+ ions might also enhance osteoblastogenesis across the TRPM7/PI3K signaling pathway, as PI3K phosphorylation occurs via TRPM7 and leads to the migration of osteoblasts, whereas knockdown of TRPM7 gene decreased alkaline phosphatase (ALP) activity [33].
Human mesenchymal stem cell (hMSC) studies demonstrated that TRPM7 and MagT1 may be important for osteoblastogenesis due to the increase in their expression during differentiation into osteoblasts. Moreover, downregulation of TRPM7 and MagT1 leads to autophagy, which could lead to accelerating osteoblastic differentiation, leading the authors to describe TRPM7 and MagT1 as possible osteoblastogenesis regulators [76,77]. However, others also showed that higher Mg2+ may have adverse effects on bone metabolism, maybe in part due to changes in the expression of TRPM7 and in the homeostasis of other important metal ions for bone tissue, in addition to inhibiting ALP activity in osteoblasts [34].
In experimental models, dietary Mg2+ deficiency leads to decreased bone mineral content in the trabecular compartment, decreased osteoblast and increased osteoclast numbers, reduced alkaline phosphatase (ALP) and osteocalcin, and elevated TNF-α, substance P, and IL-1 observed in the bone marrow microenvironment following immunohistochemical analysis in the bone [35,78]. In addition, observed changes were seen in the receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin (OPG) rates in the tibia of animals with Mg2+ deficiency, suggesting greater stimulus for bone resorption [79].
In view of these studies from human and experimental models, Mg2+ deficiency can affect bone health and is related to low BMD and bone mass, where the latter are conditions that can trigger an increase of adipogenesis, leading to an imbalance of osteoblasts/adipocytes in bone marrow [80,81,82,83]. In this way, Mg2+ deficiency could indirectly affect the osteoblast/adipocyte taxa. An in vitro study with cell line C3H10T1/2 verified that the increase in H2O2, a reactive oxygen species (ROS), resulted in higher adipogenesis, decreased sirtuin-1 (SIRT1) protein expression, increased expression levels of Kruppel-like factor 5 (KLF5) and peroxisome proliferator-activated receptor (PPAR) γ2, and decreased RUNX2 levels, resulting in enhancing adipogenesis to the detriment to osteogenesis [84]. Mg2+ deficiency is also a condition that leads to oxidative stress, increasing H2O2 and lipid peroxidation [85,86,87]; therefore, Mg2+ deficiency could affect the osteoblast/adipocyte balance not only by increasing adipogenesis due to alterations in bone homeostasis, but also by raising oxidative stress, elevating inducible nitric oxide synthase (iNOS) and H2O2 [84,88,89]. Our group and others also observed previously that nutritional aspects are extremely relevant for the osteoblast/adipocyte balance [90,91]. It is worth mentioning that, although some studies showed that bone marrow adipocytes may have a relevant role in hematopoiesis [91,92], an increase in these cells in bone marrow is seen as a negative hematopoiesis regulator [72] and is related to several diseases [81,93,94].

2.1.2. Mg2+ and Endothelial Cells

The microarchitecture of the medullary microenvironment is composed of different types of vessels (arterial and sinusoidal vessels, arterioles, and capillaries), resulting in an upper vascularized network composed of endothelial cells (ECs), which are indispensable for modulating HSCs [95,96]. ECs in the bone marrow microenvironment are a crucial component for niche vascular homeostasis, especially for their role in sustaining HSCs [97]. Stem-cell factor (SCF) is important for the maintenance of HSCs, and it was reported that SCF inhibition from ECs using Tie2-cre leads to exhausting HSCs in bone marrow, reinforcing the significance of ECs for the support of HSCs [98]. Moreover, ECs also support self-renewal and expansion of HSCs with the involvement of Notch signaling [99,100].
The sinusoidal and arterial niches seem to influence the balance between proliferation and quiescence of HSCs. Many studies found that the permeability properties of vessels play a central role in this balance. Arterial vessels with less permeability are capable of maintaining HSCs in a resting state. On the other hand, higher-permeability sinusoids promote HSCs and progenitor cells and, therefore, alterations in these microenvironments may be related to hematological abnormalities [96,101,102]. It is unknown how Mg2+ influences endothelial cells from bone marrow. However, Mg2+ deficiency is a condition that triggers endothelial dysfunction [103]. In vitro, murine microvascular endothelial 1G11 cells cultured with lower Mg2+ resulted in less proliferation, altered migration, and increased IL-6, NOS activity, and vascular cell adhesion molecule (VCAM) expression [36], whereas increased levels of plasminogen activator inhibitor (PAI-1) and IL-1 were also observed during Mg2+ deficiency [104].
Other studies, using different sources of endothelial cells, also showed interesting results. In human umbilical vein endothelial cells (HUVECs), Mg2+ deficiency triggered higher NF-ĸB activation, along with increases in IL-8, regulated upon activation, normal T cell expressed and secreted (RANTES), and granulocyte macrophage colony-stimulating factor (GM-CSF) [37]. The TRPM7 channel is permeable to Mg2+ and relevant for intracellular homeostasis of this mineral, and it appears to play an important role in endothelial function [105]. Human microvascular endothelial cells (HMECs) cultured with a lower concentration of Mg2+ resulted in impaired proliferation, increasing the number of cells in the gap (G0–G1) phase of the cell cycle and downregulation of TRPM7, whereas silencing of TRPM7 showed similar results in this model [38]. In an experimental model, TRPM7 and MagT1 were seen as relevant for Mg2+ homeostasis in endothelial cells [39]. In this same study, the deficiency of Mg2+ increased the levels of reactive oxygen species (ROS), prostaglandin E2 (PGE2), TNF-α, and IL-1β, and altered the messenger RNA (mRNA) expression of ICAM-1 and VCAM-1. In addition, less viability and cell proliferation were observed during Mg2+ deficiency, along with changes in endothelial permeability, and a possible role in regulating the integrity of the endothelial barrier through the sphingosine-1-phosphate receptor 1 (S1P1)–Ras-related C3 botulinum toxin substrate 1 (Rac1) pathway. On the other hand, the authors found that treatment with Mg2+ was able to reestablish endothelial homeostasis [39] (Figure 1).
In humans, the influence of Mg2+ in endothelial function is controversial. On the one hand, Mg2+ supplementation appears to be beneficial for endothelial function. A randomized, double-blind clinical trial with hypertensive women showed that Mg2+ supplementation improved endothelial function [40]. A meta-analysis evaluated the effects of Mg2+ supplementation on endothelial function and found that treatment with Mg2+ improves the flow-mediated dilation (FMD) parameter [106]. On the other hand, a study examined the effects of Mg2+ supplementation on the endothelial function of overweight and obese individuals, middle-aged adults, and the elderly, subjected to a daily magnesium supplement of 350 mg for 24 weeks. There was no observed improvement in soluble vascular cell adhesion molecule (sVCAM)-1, soluble intercellular adhesion molecule (sICAM)-1, and soluble endothelial selectin (sE-selectin), along with no change in FMD markers of endothelial function or inflammatory parameters [41].
Taken together, data from the literature show that Mg2+ influences endothelial function, partly due to the increase in ROS, activation of the NF-ĸB pathway, and alteration of the expression of ICAM-1 and VCAM-1 during Mg2+ deficiency. However, while data from in vitro studies show an improvement in endothelial function with higher Mg2+ concentration, in humans, the data are conflicting. It is highly relevant to expand research focused directly on the relationship between changes in Mg2+ homeostasis and its impact on endothelial cells that are part of the bone marrow microenvironment, to try to understand how these changes could affect HSC homeostasis and hematopoietic progenitors.

2.1.3. Influence of Mg2+ in Macrophages

Bone marrow-resident macrophages are essential for homeostasis of the medullary microenvironment due to its capacity to act in the maintenance of HSC niches and to regulate hematopoiesis [107,108]. Macrophages appear to regulate the retention of HSCs in the bone marrow, altering the expression of genes such as CXCL12, ANGPT1, KITL, and VCAM1 in Nestin+ niche cells from bone marrow, and they are fundamental for normal erythropoiesis [109,110]. Recently, a subset of VCAM-1+ macrophages named “usher cells” were demonstrated to be involved in the homing and retention of HSCs and hematopoietic progenitors in a zebrafish model, reinforcing the pivotal role of these cells in the control of bone marrow niches [111]. Furthermore, macrophages are essential for immune regulation, mainly due to their enormous capacity to produce various cytokines, which control both immune response and hematopoiesis [112]. Cytokines are too important for hematopoiesis [113], and the intra- and extracellular concentration of Mg2+ can affect their production by leading to the activation of several immune cells including macrophages, but the mechanisms are not entirely clear and the data are conflicting [114]. However, several studies agree that the main initiating factors that contribute to the activation of immune cells and consequently increased inflammatory cytokines during Mg2+ deficiency are the increase in intracellular substance P and Ca2+ (since Mg2+ is a natural blocker of the latter), the rise in oxidative stress, and greater activation of the NF-ĸB pathway [115,116,117].
Additional studies using different sources of macrophages also show an interesting influence of Mg2+ levels. In rat alveolar macrophages, Mg2+ deficiency in vitro led to an increase of TNF-α and IL-1 mRNA levels with the involvement of Ca2+ signaling pathways [42]. In this same study, when these cells were cultured in a control medium or lower Mg2+ concentration and stimulated with lipopolysaccharide (LPS), there was a rise in the lower Mg2+ condition for both cytokines compared to controls. Yet, Mg2+ deficiency is able to increase NO production via iNOS [118]. In order to investigate how different types of liver cells respond to Mg2+ deficiency in vitro, RAW264.7 cells grown in Mg2+-deficient medium showed increased expression of the Nqo1 and Prdx1 genes related to protection against oxidative stress, and this increase could be secondary to the rise in oxidative stress that occurs during Mg2+ deficiency [119]. In addition, low Mg2+ concentration showed an increase in NF-κB activity in RAW264.7 cells, in addition to alterations in the production and expression of high-mobility group box 1 (HMGB1), a molecule with inflammatory properties [43]. On the other hand, studies showed that increased Mg2+ concentration is able to decrease the proinflammatory cytokine production in mononuclear cells from human and animal sources, by inhibiting the nuclear translocation and phosphorylation of NFκB and the rise in basal IĸBα levels [44,120]. Moreover, the effects of preventing inflammation by increased Mg2+ concentration in macrophages also include modulation of PI3K/Akt pathway activity, downregulation of TNF-α and IL-1β, enhanced M2 macrophage phenotype, and BMP2 and VEGF expression, with the latter seen in cell subject biomaterials coated with Mg2+ [121,122,123] (Figure 1).
Mg2+ deficiency results in low-grade chronic inflammation, activating macrophages in tissues and immune cells in peripheral blood, and elevating the concentration of cytokines, such as IL-1, IL-6, and TNF-α [6]. IL-1 and TNF-α are known to induce myelopoiesis, whereas the latter is involved in mechanisms of cell activation and survival in the bone marrow, and both can influence hematopoiesis according to the intensity and duration of their production [124]. Furthermore, it was shown that IL-1 induces PU.1 activation in HSCs with NF-κB pathway involvement, and that chronic exposure to this cytokine triggers changes in HSC homeostasis, principally in the autorenovation mechanisms [125]. In addition, a rise in TNF-α and IL-6 is related to hematopoietic diseases, such as myelodysplasic syndrome and disruption of erythropoiesis [110]; therefore, Mg2+ deficiency could negatively affect hematopoiesis. However, it is important to mention that most studies that evaluated the influence of Mg2+ in macrophages were performed in vitro, with lineage cells, while many of them were cultured with supraphysiological or the lowest concentrations of Mg2+. Thus, it is difficult to conclude how changes in vivo in Mg2+ homeostasis may influence human macrophages in the bone marrow, and comprehensive studies on the topic are required.

2.2. Mg2+ and Erythropoiesis

Erythropoiesis occurs from pluripotent stem cells in the bone marrow, with the erythroid progenitor being BFU-E (erythroid explosion-forming unit), which results in colony-forming units (CFU-E), mature erythroid precursors, reticulocytes, and red blood cells [126]. Erythroid differentiation and maturation occur in erythroblastic islands, and these complex events of proliferation, differentiation, and maturation depend on several factors, such as GATA-binding protein 1 and 2 (GATA 1 and 2), SCF, IGF (insulin-like growth factor), BPA (erythroid burst-promoting activity), IL-3, and EPO (erythropoietin) [127,128,129,130], in addition to nutritional aspects, like iron, folate, and B12 vitamin [131]. Yet, the influence of Mg2+ on the erythropoiesis process in the bone marrow is not clear. It is known that there is a relationship between Mg2+ and anemia; nevertheless, most studies focused on the importance of this mineral in peripheral blood erythrocytes.
Studies carried out since the 1930s have shown a relationship between Mg2+ status and erythrocytes in experimental models. First, it was identified that the Mg2+ content in erythrocytes was higher in cases of anemia [132]. Subsequently, a series of studies showed that Mg2+ deficiency triggered fetal growth restriction and microcytic anemia, fragmentation of red blood cells, and impaired osmotic fragility in offspring from deficient mothers and in adult rats, while the latter also displayed reticulocytosis, which was attributed to changes in the energy metabolism and membrane of erythrocytes [133,134,135]. Moreover, red blood cells (RBC) from animals with Mg2+ deficiency seem to age faster, whereas reticulocytosis indicates that the bone marrow might maintain erythropoiesis during low plasma Mg2+ concentration [45]. However, a study showed that Mg2+ deficiency increased Fe absorption and concentration in many tissues, but reduced the number of RBCs, possibly due to ineffective erythropoiesis [46]. Macrocytic anemia and decreased exercise capacity were also observed in rats after dietary Mg2+ deficiency, in addition to varying the content of K+ and Na+, raising the activity of cotransport of K–CI, which is related to volume and density in RBC, and decreasing of glutathione in erythrocytes [136,137,138,139].
In humans, the influence of Mg2+ status on erythrocytes was also investigated. In preeclampsia, erythrocyte deformability and, consequently, microcirculation are reduced, and Mg2+ therapy was able to increase the deformability of these cells [140,141]. A cross-sectional study with adults evaluated the association between consumption of Mg2+ and Fe with anemia, and found an inverse association between Mg2+ intake and anemia [47]. Researchers analyzed data from the 2009 China Health and Nutrition Survey and verified an association between increased serum Mg2+ and decreased risk of anemia in women and men from nine provinces of China. However, this association was significantly greater in women and dependent on ferritin levels [48]. In addition, the dietary pattern (traditional vs. modern pattern) was analyzed in elderly subjects, and a positive association was found between the traditional dietary pattern and anemia with the influence of serum Mg2+ [142]. A cross-sectional study with 180 pregnant women (up to 14 weeks of gestation) from Khartoum in Sudan, showed that 65.0% and 57.2% had anemia and Mg2+ deficiency, respectively, and that low levels of serum ferritin and Mg2+ were associated with anemia [49]. On the other hand, Mg2+ supplementation seems to increase the hemoglobin levels and counts of erythrocytes [50].
EPO is a glycoprotein produced mainly by the kidneys and is influenced by hypoxia, with a pivotal role in the mechanisms of survival, proliferation, and differentiation of erythrocytes in the bone marrow [143]. Anemia is a frequent finding in individuals undergoing hemodialysis, mainly due to the decrease in EPO concentrations, but also due to the impaired response to EPO, and an increase in serum Mg2+ seems to decrease the risk of a lesser response to EPO [144]. In vitro, lower Mg2+ concentrations inhibited the activity of HIF-1α (hypoxia- inducible factor) mediated by ROS through the activation of NF-κB involving T-type calcium channels, with HIFs being an important factor in the promotion of EPO levels [145,146].
Although several studies showed an association between the concentration of Mg2+ and the development of anemia and its influence on the erythrocytes in peripheral blood, there is no direct evidence to support how the intra- and extracellular concentration of Mg2+ may affect erythropoiesis in the bone marrow. However, we suppose that Mg2+ deficiency may partially affect erythropoiesis by altering the NF-κB pathway in macrophages and iron homeostasis, indirectly triggering changes in the membrane and accelerating the aging and destruction of RBCs. Nevertheless, research showing how Mg2+ concentration could directly affect erythropoiesis in the bone marrow and how and which pathways are related is important and remains open to investigation. As human studies show a relationship between hypomagnesemia and anemia, it is important to encourage more studies on the topic, given that the correction of hypomagnesemia in addition to Fe could perhaps be considered for the treatment of these hematological alterations.

2.3. Mg2+ and Granulopoiesis

Among the cells of granulocytic lineage, Mg2+ deficiency affects neutrophils most severely, but eosinophils and mast cells can also be affected. Hypomagnesemia triggers a boost of eosinophils in the peripheral blood, increasing the number of mast cells in several tissues and in the bone marrow, impairing their function [51,52,53,147].
Neutrophilia is a common finding during hypomagnesemia in experimental models [4,54,148]. In general, the main justification for this is due to the increased inflammation observed during the deficiency of this mineral. Nevertheless, the mechanisms behind these observations are unclear, and an issue remains if this neutrophilia is a consequence of the inflammatory stimulus resulting from Mg2+ deficiency or if molecular changes occur in the development, differentiation, and maturation of this lineage in the bone marrow even before the development of inflammatory phenotype. Perhaps, it is a combination of these two possibilities. However, there is little direct evidence to support which molecular alterations could be involved in the development of neutrophils in the bone marrow during hypomagnesemia.
Neutrophils are leukocytes that act in the first cell line of defense of organisms against various types of infectious agents, through the mechanism of phagocytosis and production of cytotoxic molecules, and it is not by chance that most bone marrow leukocytes are granulocytic precursors [149]. It is not yet clear, but Mg2+ deficiency seems to alter the differentiation and maturation mechanisms of myeloid cells, favoring the granulocytic lineage during the deficiency of this mineral. Alterations in cell-cycle control, intracellular Mg2+ levels, and Mg2+ compartmentalization may be the main mechanisms behind the neutrophilia observed during hypomagnesemia in vitro [26]. In vivo, an experimental study analyzed the repercussions of long-term consumption of an Mg2+-deficient diet on the bone marrow of rats. The authors found that more than half of the bone marrow samples were hypercellular, with a greater number of granulocytic cells, and one animal developed leukemia with granulocytic infiltrate in several organs. Furthermore, cells from granulocytic infiltrate inoculated in newborn animals resulted in leukemia in half of the animals after 3 months of inoculation [15].
The emergence and the steady state of granulopoiesis in the bone marrow are highly regulated, mainly by G-CSF, GM-CSF, CCAAT-enhancer-binding proteins (C/EBPα and C/EBPβ), IL-6, and Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathways [150,151,152]. We conjecture that Mg2+ status may alter these signaling pathways, given that changes in granulopoiesis, mainly neutrophilia, occur during hypomagnesemia. Nevertheless, there is no direct evidence of the relationship between Mg2+ and these molecular pathways to support this claim, and the repercussions of hypomagnesemia in these signaling pathways and in the granulopoiesis process remain to be elucidated. Additionally, lower Mg2+ levels affect the cell-cycle control and aging cell process, beyond upregulation of inflammatory markers, and these changes may affect not only granulopoiesis but also hematopoiesis in general. Yet, it is unknown if Mg2+ may affect the C–X–C motif chemokine 12 (CXCL12)/CXCR4 axis that controls the traffic of neutrophils in the bone marrow or whether hypomagnesemia could lead to alterations in dendritic cells [153]. Dendritic cells seem to control the traffic of neutrophils from bone marrow, and their decrease triggers a boost of neutrophils in the peripheral blood, even in the lack of infection [154].

2.4. Influence of Mg2+ in Lymphopoiesis

Studies showed that extra- and intracellular Mg2+ concentrations are important for the activation and proliferation of lymphocytes, and that Mg2+ deficiency may affect the function of these cells in peripheral blood, decreasing immunoglobulin production and the number of cells that produce antibodies [2,155,156]. However, the influence of Mg2+ homeostasis on the lymphopoiesis process and the progenitor’s lymphoid in bone marrow is less elucidated. Experimental studies showed that severe Mg2+ deficiency leads to bone marrow changes that appear to occur at the same time as thymic changes, resulting in hyperplastic bone marrow, lymphoproliferative disorder, and leukemia [157,158]. In addition, dietary Mg2+ deficiency resulted in thymic changes, impairing its function, triggering increased necrosis, apoptosis, and phagocytosis, and favoring a tumor microenvironment in rats [86,159,160]. In humans, it was observed that patients with acute lymphocytic leukemia (ALL) have reduced levels of Mg2+ in serum and hair; these changes appear to occur in part due to bone alterations resulting from the treatment of the disease [161,162,163,164]. However, the consequences of hypomagnesemia for the health of individuals with hematological diseases and its influence on the development of these diseases are not clear.
The role of TRPM7 and MagT1 in the function and development of lymphocytes is most frequently investigated [165]. Nevertheless, the relationship among intracellular Mg2+, TRPM7, and MagT1 homeostasis in the development and function of lymphocytes remains to be established and is not fully understood. In vitro, DT40 cells that lack the TRPM7 gene showed arrest of the cell cycle in the G0–G1 phase and led to changes in the PI3K /Akt/mammalian target of rapamycin (mTOR)/S6K pathway, but the increased Mg2+ concentration in these cells improved the proliferation levels [166] (Figure 1). A study showed that the absence of the TRPM7 channel in B cells from mice abolished mature B cells in the spleen, lymph nodes, and peripheral blood, and it led to an arrest in the development of pre-pro-B cells and pro-B cells. In addition, it impaired serum levels of immunoglobulins (IgM, IgG, and IgA) and triggered a boost of myeloid cells, especially neutrophils, in the spleen and peripheral blood. In the same study, increased Mg2+ concentration in vitro was able to partially improve the development of B cells [167]. However, the same was not noted in T cells, where the deletion of the TRPM7 gene did not trigger changes in Mg2+ homeostasis, while impairing thymopoiesis [7].
One of the most relevant studies about the relationship between lymphocytes and Mg2+ was described in the XMEN syndrome (X-linked immunodeficiency Mg2+ defect, Epstein–Barr virus infection, and neoplasia), which was first described as Magt1 loss affecting intracellular Mg2+ homeostasis and leading to defective T-cell immune responses and uncontrolled EBV infection with increased susceptibility to EBV+ lymphoma [168]. This syndrome is a rare primary immunodeficiency caused by hemizygous loss-of-function mutations in the X-linked MagT1 gene in males [169]. Magt1 was initially recognized as an Mg2+ transporter, and early studies placed it as a plasma membrane protein; however, more recent data also postulated that Magt1 is localized in the endoplasmic reticulum and is a subunit of the oligosaccharyltransferase (OST) complex and more specifically of the STT3B complex [170]. In this way, the XMEN syndrome and its relationship with Mg2+ has now been revised. As the molecular relationship to OST subunits and complexities of Mg2+ suggested that pivotal manifestations of XMEN syndrome may rotate around defective glycosylation, in addition to or instead of alterations in Mg2+ transport [171]. However, a study from the same group also showed that glycosylation is sensitive to Mg2+ levels and that reduced Mg2+ impairs immune cell function via the loss of specific glycoproteins [172].
Nevertheless, Mg2+ homeostasis is too important for restoring the functions of T cells of individuals that suffer from genetic deficiencies in MagT1 and mutations in the kinase domain of interleukin-2-inducible kinase (ITK). These mutations display impaired function in T cells, such as changes in activation after T-cell receptor (TCR) stimulation, cytotoxicity, and degranulation, resulting in a great predisposition to infections by EBV that is associated with a high risk of development of lymphoma; hence, Mg2+ supplementation is important for improving the function of T cells in these conditions [8,173].

2.5. Influence of Mg2+ in Thrombopoiesis

Regarding thrombopoiesis, the influence of Mg2+ in megakaryocytes is not clear. Mg2+ is important for platelet homeostasis. Studies showed that lower Mg2+ concentrations are involved with platelet-dependent thrombosis and hyperreactivity, whereas increased Mg2+ concentration seems to inhibit platelet aggregation, partially altering intracellular Ca2+ levels and decreasing the production of molecules involved in this process, such as eicosanoids [174,175,176]. Research found that changes in the intracellular Mg2+ concentration in platelets from individuals with obesity and diabetes could be related to the development of future disorders in the coagulation process [177]. A cross-sectional study with Chinese women and men observed that a rise in serum Mg2+ level was associated with increased platelet numbers and a lower risk of development of thrombocytopenia [55]. Nevertheless, few studies investigated the role of intra- and extracellular Mg2+ concentrations in megakaryocytes in the bone marrow. Mg2+ deficiency may promote defects in platelet biogenesis due to changes in the cytoskeleton, promoting changes in platelet function [178]. In an experimental model, dietary Mg2+ deficiency impaired megakaryocytes from bone marrow, resulting in a decrease in the number and larger shape than the cells of the control animals [56]. A study showed that disorders in the TRPM7 channel and Mg2+ homeostasis in megakaryocytes trigger macrothrombocytopenia by altering the activity of the nonmuscular myosin protein IIA (NMMIIA) and the cytoskeleton, affecting the maturation of platelets in the bone marrow [16].

3. Conclusions and Perspectives

Mg2+ is the fourth most abundant mineral in the body showing a significant positive correlation with the protein synthesis rate, suggesting a key role of this mineral in the regulation of protein synthesis and in the cell proliferation rate in normal tissue cell populations, especially those with a high turnover such as the hematopoietic system. Due to the importance of this mineral in hematopoiesis, an imbalance can disrupt the hematopoiesis process, as well as the effective activities of mature blood cells. In conclusion, it is crucial to understand the impact of Mg2+ on the correct hematopoietic functions, to understanding the mechanisms, and to understand when or how some therapeutic intervention is necessary. However, despite the existence of several studies showing the extensive role of Mg2+, more studies are necessary to address the exact impact of this mineral on the hematopoietic system.

Author Contributions

F.d.S.L. and R.A.F. designed the study and wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by grants from the Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP; grant 2018/25813-8).

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflict of interest.

Abbreviations

1G11Murine pulmonary vascular endothelial cell
AktProtein kinase B
ALLAcute lymphocytic leukemia
ALPAlkaline phosphatase
BFU-EBurst forming unit, erythroid
BMDBone mineral density
BMP2Bone morphogenetic protein 2
C/EBPαCCAAT-enhancer-binding protein α
C/EBPβCCAAT-enhancer-binding protein β
C3H10T1/2Murine C3H embryo sarcoma
Ca2+Calcium
c-fosMember of Fos family of transcription factors
CFU-EColony-forming unit, erythroid
COL10A1Collagen type X alpha 1 chain
CXCL12C–X–C motif chemokine 12
Angpt1Angiopoietin 1
CXCL12C–X–C motif chemokine 12
CXCR4C–X–C chemokine receptor type 4
G-CSFGranulocyte colony-stimulating factor
DC-STAMPDendritic cell-specific transmembrane protein
DNADeoxyribonucleic acid
DT40 cellChicken B cell line
EBVEpstein–Barr virus
ECMExtracellular matrix
EPOErythropoietin
FeIron
FMDFlow-mediated dilation
GATAGATA-binding protein 1
G-CSFGranulocyte colony-stimulating factor
GM-CSFGranulocyte macrophage colony-stimulating factor
H2O2Hydrogen peroxide
hFOB1.19Human bone osteoblast; SV40 large T antigen transfected
HIF1-αHypoxia-inducible factor 1α
HMGB1High-mobility group box 1
hMSCsHuman mesenchymal stem cells
HSCHematopoietic stem cell
HUVECHuman umbilical vein endothelial cell
IgAImmunoglobulin A
IGF2Insulin-like growth factor 2
IgGImmunoglobulin G
IgMImmunoglobulin M
IL-1Interleukin-1
IL-6Interleukin-6
IL-8Interleukin-8
iNOSInducible nitric oxide synthase
ITKInterleukin-2-inducible kinase
JAK/STATJanus kinase/signal transducer
KPotassium
KLF5Kruppel-like factor 5
MagT1Magnesium transporter 1
Mg2+Magnesium
mTORMammalian target of rapamycin
NaSodium
NF-ĸBNuclear factor kappa B
NKG2DNatural killer group 2 member D
NMMIIANonmuscular myosin protein IIA
OPGOsteoprotegerin
OSTOligosaccharyltransferase
PCNAProliferating cell nuclear antigen
CRPC-reactive protein
PGC-1 αPeroxisome proliferator-activated receptor gamma coactivator 1-alpha
PGE2Prostaglandin E2
PI3-kinasePhosphoinositide 3-kinase
PPARγ2Peroxisome proliferator-activated receptor γ2
PTHParathyroid hormone
PU.1Transcription factor PU.1
Rac1Ras-related C3 botulinum toxin substrate 1
RANKLReceptor activator of nuclear factor kappa Β ligand
RANTESRegulated upon activation, normal T cell expressed and secreted
RBCRed blood cells
RNARibonucleic acid
ROSReactive oxygen species
RUNX2RUNX family transcription factor 2
S1P1Sphingosine-1-phosphate receptor 1
S6KRibosomal S6 kinase
SaOS-2Human osteosarcoma cell line
SCFStem-cell factor
sE-selectinSoluble endothelial selectin
sICAM-1Soluble intercellular adhesion molecule 1
SIRT1Sirtuin-1
STATSignal transducer and activator of transcription
STT3BOligosaccharyltransferase complex catalytic subunit B
sVCAM-1Soluble vascular cell adhesion molecule 1
TCRT-cell receptor
TNF-αTumor necrosis factor α
TRPM7Transient receptor potential cation channel subfamily M member 7
VCAM1Vascular cell adhesion molecule 1
VEGFVascular endothelial growth factor

References

  1. Nielsen, F.H. Dietary Magnesium and Chronic Disease. Adv. Chronic Kidney Dis. 2018, 25, 230–235. [Google Scholar] [CrossRef]
  2. Elin, R.J. The Effect of Magnesium Deficiency in Mice on Serum Immunoglobulin Concentrations and Antibody Plaque-Forming Cells. Exp. Boil. Med. 1975, 148, 620–624. [Google Scholar] [CrossRef] [PubMed]
  3. Wolf, F.I. Magnesium in cell proliferation and differentiation. Front. Biosci. 1999, 4, D607–D617. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Malpuech-Brugère, C.; Nowacki, W.; Daveau, M.; Gueux, E.; Linard, C.; Rock, E.; Lebreton, J.-P.; Mazur, A.; Rayssiguier, Y. Inflammatory response following acute magnesium deficiency in the rat. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 2000, 1501, 91–98. [Google Scholar] [CrossRef] [Green Version]
  5. Van Orden, R.; Eggett, D.L.; Franz, K.B. Influence of graded magnesium deficiencies on white blood cell counts and lymphocyte subpopulations in rats. Magnes. Res. 2006, 19, 93–101. [Google Scholar] [PubMed]
  6. Nielsen, F.H. Magnesium deficiency and increased inflammation: Current perspectives. J. Inflamm. Res. 2018, 11, 25–34. [Google Scholar] [CrossRef] [Green Version]
  7. Jin, J.; Desai, B.N.; Navarro, B.; Donovan, A.; Andrews, N.C.; Clapham, D.E. Deletion of Trpm7 Disrupts Embryonic Development and Thymopoiesis Without Altering Mg2+ Homeostasis. Science 2008, 322, 756–760. [Google Scholar] [CrossRef] [Green Version]
  8. Howe, M.K.; Dowdell, K.; Roy, A.; Niemela, J.E.; Wilson, W.; McElwee, J.J.; Hughes, J.D.; Cohen, J.I. Magnesium Restores Activity to Peripheral Blood Cells in a Patient With Functionally Impaired Interleukin-2-Inducible T Cell Kinase. Front. Immunol. 2019, 10, 2000. [Google Scholar] [CrossRef] [Green Version]
  9. Yoshizawa, S.; Chaya, A.; Verdelis, K.; Bilodeau, E.A.; Sfeir, C. An in vivo model to assess magnesium alloys and their biological effect on human bone marrow stromal cells. Acta Biomater. 2015, 28, 234–239. [Google Scholar] [CrossRef] [Green Version]
  10. Luthringer-Feyerabend, B.J.; Willumeit-Römer, R. Effects of magnesium degradation products on mesenchymal stem cell fate and osteoblastogenesis. Gene 2016, 575, 9–20. [Google Scholar] [CrossRef] [Green Version]
  11. Lima, F.D.S.; Romero, A.B.D.R.; Hastreiter, A.; Nogueira-Pedro, A.; Makiyama, E.; Colli, C.; Fock, R.A. An insight into the role of magnesium in the immunomodulatory properties of mesenchymal stem cells. J. Nutr. Biochem. 2018, 55, 200–208. [Google Scholar] [CrossRef] [PubMed]
  12. Zheng, J.; Mao, X.; Ling, J.; Chen, C.; Zhang, W. Role of Magnesium Transporter Subtype 1 (MagT1) in the Osteogenic Differentiation of Rat Bone Marrow Stem Cells. Boil. Trace Element Res. 2015, 171, 131–137. [Google Scholar] [CrossRef] [PubMed]
  13. Taichman, R.S.; Emerson, S.G. Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor. J. Exp. Med. 1994, 179, 1677–1682. [Google Scholar] [CrossRef] [PubMed]
  14. Taichman, R.S.; Reilly, M.; Emerson, S. Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures. Blood 1996, 87, 518–524. [Google Scholar] [CrossRef] [PubMed]
  15. McCreary, P.A.; Battifora, H.A.; Hahneman, B.M.; Laing, G.H.; Hass, G.M.; Singh, K. Leukocytosis, Bone Marrow Hyperplasia and Leukemia in Chronic Magnesium Deficiency in the Rat. Blood 1967, 29, 683–690. [Google Scholar] [CrossRef]
  16. Stritt, S.; Nurden, P.; Favier, R.; Favier, M.; Ferioli, S.; Gotru, S.K.; Van Eeuwijk, J.M.M.; Schulze, H.; Nurden, A.T.; Lambert, M.P.; et al. Defects in TRPM7 channel function deregulate thrombopoiesis through altered cellular Mg2+ homeostasis and cytoskeletal architecture. Nat. Commun. 2016, 7, 11097. [Google Scholar] [CrossRef]
  17. Krishnamoorthy, M.; Wasim, L.; Buhari, F.H.M.; Zhao, T.; Mahtani, T.; Ho, J.; Kang, S.; Deason-Towne, F.; Perraud, A.-L.; Schmitz, C.; et al. The channel-kinase TRPM7 regulates antigen gathering and internalization in B cells. Sci. Signal. 2018, 11, eaah6692. [Google Scholar] [CrossRef] [Green Version]
  18. Yee, N.S.; Kazi, A.A.; Yee, R.K. Cellular and Developmental Biology of TRPM7 Channel-Kinase: Implicated Roles in Cancer. Cells 2014, 3, 751–777. [Google Scholar] [CrossRef]
  19. Zierler, S.; Sumoza-Toledo, A.; Suzuki, S.; Dúill, F. Ó; Ryazanova, L.V.; Penner, R.; Ryazanov, A.G.; Fleig, A. TRPM7 kinase activity regulates murine mast cell degranulation. J. Physiol. 2016, 594, 2957–2970. [Google Scholar] [CrossRef] [Green Version]
  20. Nadolni, W.; Zierler, S. The Channel-Kinase TRPM7 as Novel Regulator of Immune System Homeostasis. Cells 2018, 7, 109. [Google Scholar] [CrossRef] [Green Version]
  21. Sun, Y.; Sukumaran, P.; Singh, B.B. Magnesium-Induced Cell Survival Is Dependent on TRPM7 Expression and Function. Mol. Neurobiol. 2019, 57, 528–538. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Cao, R.; Meng, Z.; Liu, T.; Wang, G.; Qian, G.; Cao, T.; Guan, X.; Dan, H.; Xiao, Y.; Wang, X. Decreased TRPM7 inhibits activities and induces apoptosis of bladder cancer cells via ERK1/2 pathway. Oncotarget 2016, 7, 72941–72960. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Zou, Z.G.; Rios, F.J.; Montezano, A.C.; Touyz, R.M. TRPM7, Magnesium, and Signaling. Int. J. Mol. Sci. 2019, 20, 1877. [Google Scholar] [CrossRef] [Green Version]
  24. Ikari, A.; Sawada, H.; Sanada, A.; Tonegawa, C.; Yamazaki, Y.; Sugatani, J. Magnesium deficiency suppresses cell cycle progression mediated by increase in transcriptional activity of p21Cip1 and p27Kip1 in renal epithelial NRK-52E cells. J. Cell. Biochem. 2011, 112, 3563–3572. [Google Scholar] [CrossRef] [PubMed]
  25. Hartwig, A. Role of magnesium in genomic stability. Mutat. Res. Mol. Mech. Mutagen. 2001, 475, 113–121. [Google Scholar] [CrossRef]
  26. Covacci, V.; Bruzzese, N.; Sgambato, A.; Di Francesco, A.; Russo, M.A.; Wolf, F.I.; Cittadini, A. Magnesium restriction induces granulocytic differentiation and expression of p27Kip1 in human leukemic HL-60 cells. J. Cell. Biochem. 1998, 70, 313–322. [Google Scholar] [CrossRef]
  27. Wu, L.; Witte, F.M.; Schilling, A.F.; Willumeit-Römer, R.; Luthringer-Feyerabend, B.J. Effects of extracellular magnesium extract on the proliferation and differentiation of human osteoblasts and osteoclasts in coculture. Acta Biomater. 2015, 27, 294–304. [Google Scholar] [CrossRef]
  28. Mammoli, F.; Castiglioni, S.; Parenti, S.; Cappadone, C.; Farruggia, G.; Iotti, S.; Davalli, P.; Maier, J.A.; Grande, A.; Frassineti, C. Magnesium Is a Key Regulator of the Balance between Osteoclast and Osteoblast Differentiation in the Presence of Vitamin D3. Int. J. Mol. Sci. 2019, 20, 385. [Google Scholar] [CrossRef] [Green Version]
  29. Martin, H.; Richert, L.; Berthelot, A. Magnesium deficiency induces apoptosis in primary cultures of rat hepatocytes. J. Nutr. 2003, 133, 2505–2511. [Google Scholar] [CrossRef] [Green Version]
  30. Ohyama, T. New Aspects of Magnesium Function: A Key Regulator in Nucleosome Self-Assembly, Chromatin Folding and Phase Separation. Int. J. Mol. Sci. 2019, 20, 4232. [Google Scholar] [CrossRef] [Green Version]
  31. Díaz-Tocados, J.M.; Herencia, C.; Martínez-Moreno, J.M.; De Oca, A.M.; Rodríguez-Ortiz, M.E.; Vergara, N.; Blanco, A.; Steppan, S.; Almadén, Y.; Rodríguez, M.; et al. Magnesium Chloride promotes Osteogenesis through Notch signaling activation and expansion of Mesenchymal Stem Cells. Sci. Rep. 2017, 7, 7839. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Wang, J.; Ma, X.-Y.; Feng, Y.-F.; Ma, Z.-S.; Ma, T.-C.; Zhang, Y.; Li, X.; Wang, L.; Lei, W. Magnesium Ions Promote the Biological Behaviour of Rat Calvarial Osteoblasts by Activating the PI3K/Akt Signalling Pathway. Boil. Trace Element Res. 2017, 179, 284–293. [Google Scholar] [CrossRef] [PubMed]
  33. Zhang, X.; Zu, H.; Zhao, D.W.; Yang, K.; Tian, S.; Yu, X.; Lu, F.; Liu, B.; Yu, X.; Wang, B.; et al. Ion channel functional protein kinase TRPM7 regulates Mg ions to promote the osteoinduction of human osteoblast via PI3K pathway: In vitro simulation of the bone-repairing effect of Mg-based alloy implant. Acta Biomater. 2017, 63, 369–382. [Google Scholar] [CrossRef] [PubMed]
  34. Leidi, M.; Dellera, F.; Mariotti, M.; Maier, J.A. High magnesium inhibits human osteoblast differentiation in vitro. Magnes Res 2011, 24, 1–6. [Google Scholar] [CrossRef] [PubMed]
  35. Rude, R.K.; Gruber, H.; Wei, L.; Frausto, A.; Mills, B. Magnesium Deficiency: Effect on Bone and Mineral Metabolism in the Mouse. Calcif. Tissue Int. 2003, 72, 32–41. [Google Scholar] [CrossRef]
  36. Bernardini, D.; Nasulewic, A.; Mazur, A.; Maier, J.A.M. Magnesium and microvascular endothelial cells: A role in inflammation and angiogenesis. Front. Biosci. 2005, 10, 1177–1182. [Google Scholar] [CrossRef] [Green Version]
  37. Ferrè, S.; Baldoli, E.; Leidi, M.; Maier, J.A. Magnesium deficiency promotes a pro-atherogenic phenotype in cultured human endothelial cells via activation of NFkB. Biochim. Et Biophys. Acta (BBA)-Mol. Basis Dis. 2010, 1802, 952–958. [Google Scholar] [CrossRef]
  38. Baldoli, E.; Maier, J.A. Silencing TRPM7 mimics the effects of magnesium deficiency in human microvascular endothelial cells. Angiogenesis 2011, 15, 47–57. [Google Scholar] [CrossRef]
  39. Zhu, D.; You, J.; Zhao, N.; Xu, H. Magnesium Regulates Endothelial Barrier Functions through TRPM7, MagT1, and S1P1. Adv. Sci. 2019, 6, 1901166. [Google Scholar] [CrossRef] [Green Version]
  40. Cunha, A.R.; D’El-Rei, J.; Medeiros, F.; Umbelino, B.; Oigman, W.; Touyz, R.M.; Neves, M.F. Oral magnesium supplementation improves endothelial function and attenuates subclinical atherosclerosis in thiazide-treated hypertensive women. J. Hypertens. 2017, 35, 89–97. [Google Scholar] [CrossRef] [Green Version]
  41. Joris, P.; Plat, J.; Bakker, S.J.L.; Mensink, R.P. Effects of long-term magnesium supplementation on endothelial function and cardiometabolic risk markers: A randomized controlled trial in overweight/obese adults. Sci. Rep. 2017, 7, 106. [Google Scholar] [CrossRef] [PubMed]
  42. Shogi, T.; Oono, H.; Nakagawa, M.; Miyamoto, A.; Ishiguro, S.; Nishio, A. Effects of a low extracellular magnesium concentration and endotoxin on IL-1beta and TNF-alpha release from, and mRNA levels in, isolated rat alveolar macrophages. Magnes. Res. 2002, 15, 147–152. [Google Scholar] [PubMed]
  43. Liu, Z.; Chang, Y.; Zhang, J.; Huang, X.; Jiang, J.; Li, S.; Wang, Z. Magnesium deficiency promotes secretion of high-mobility group box 1 protein from lipopolysaccharide-activated macrophages in vitro. J. Surg. Res. 2013, 180, 310–316. [Google Scholar] [CrossRef] [PubMed]
  44. Sugimoto, J.; Romani, A.M.; Valentin-Torres, A.M.; Luciano, A.A.; Ramirez Kitchen, C.M.; Funderburg, N.; Mesiano, S.; Bernstein, H.B. Magnesium decreases inflammatory cytokine production: A novel innate immunomodulatory mechanism. J. Immunol. 2012, 188, 6338–6346. [Google Scholar] [CrossRef] [Green Version]
  45. Elin, R.J.; Utter, A.; Tan, H.K.; Corash, L. Effect of magnesium deficiency on erythrocyte aging in rats. Am. J. Pathol. 1980, 100, 765–778. [Google Scholar]
  46. Sanchez-Morito, N.; Planells, E.; Aranda, P.; Llopis, J. Influence of magnesium deficiency on the bioavailability and tissue distribution of iron in the rat. J. Nutr. Biochem. 2000, 11, 103–108. [Google Scholar] [CrossRef]
  47. Shi, Z.; Hu, X.; He, K.; Yuan, B.; Garg, M. Joint association of magnesium and iron intake with anemia among Chinese adults. Nutrition 2008, 24, 977–984. [Google Scholar] [CrossRef]
  48. Zhan, Y.; Chen, R.; Zheng, W.; Guo, C.; Lu, L.; Ji, X.; Chi, Z.; Yu, J. Association between serum magnesium and anemia: China health and nutrition survey. Biol. Trace Element Res. 2014, 159, 39–45. [Google Scholar] [CrossRef]
  49. Eltayeb, R.; Rayis, D.A.; Sharif, M.E.; Ahmed, A.B.A.; Elhardello, O.; Adam, I. The prevalence of serum magnesium and iron deficiency anaemia among Sudanese women in early pregnancy: A cross-sectional study. Trans. R. Soc. Trop. Med. Hyg. 2019, 113, 31–35. [Google Scholar] [CrossRef]
  50. Cinar, V.; Nizamlioglu, M.; Mogulkoc, R.; Baltaci, A.K. Effects of magnesium supplementation on blood parameters of athletes at rest and after exercise. Biol. Trace Elem. Res. 2007, 115, 205–212. [Google Scholar] [CrossRef]
  51. Hungerford, G.F. Role of histamine in producing the eosinophilia of magnesium deficiency. Proc. Soc. Exp. Biol. Med. 1964, 115, 182–185. [Google Scholar] [CrossRef] [PubMed]
  52. Kraeuter, S.L.; Schwartz, R. Blood and mast cell histamine levels in magnesium-deficient rats. J. Nutr. 1980, 110, 851–858. [Google Scholar] [CrossRef] [PubMed]
  53. Bélanger, L.F. Variations in the mast cell population of skin and bone marrow in magnesium-deprived rats. The influence of sex hormones. J. Nutr. 1977, 107, 2164–2170. [Google Scholar] [CrossRef] [PubMed]
  54. Bussière, F.I.; Gueux, E.; Rock, E.; Girardeau, J.-P.; Tridon, A.; Mazur, A.; Rayssiguier, Y. Increased phagocytosis and production of reactive oxygen species by neutrophils during magnesium deficiency in rats and inhibition by high magnesium concentration. Br. J. Nutr. 2002, 87, 107–113. [Google Scholar] [CrossRef] [Green Version]
  55. Lu, L.; Zhan, Y.; Yu, J.; Sui, L. Prevalence of Thrombocytopenia and Its Association with Serum Magnesium. Biol. Trace Elem. Res. 2016, 169, 46–51. [Google Scholar] [CrossRef]
  56. Rishi, M.; Ahmad, A.; Makheja, A.; Karcher, D.; Bloom, S. Effects of reduced dietary magnesium on platelet production and function in hamsters. Lab. Investig. 1990, 63, 717–721. [Google Scholar]
  57. Maximow, A.A. Relation of Blood cells to connective tissues and endothelium. Physiol. Rev. 1924, 4, 533–563. [Google Scholar] [CrossRef]
  58. Owen, R.D.; Miller, N.E.; Bailey, C.J.; Stevenson, J.A.F. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945, 102, 400–401. [Google Scholar] [CrossRef]
  59. McCulloch, J.E.T.A. A Direct Measurement of the Radiation Sensitivity of Normal Mouse Bone Marrow Cells. Radiat. Res. 1961, 14, 213. [Google Scholar]
  60. Papayannopoulou, T.; Scadden, D.T. Stem-cell ecology and stem cells in motion. Blood 2008, 111, 3923–3930. [Google Scholar] [CrossRef]
  61. Weissman, I.L.; Shizuru, J.A. The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. Blood 2008, 112, 3543–3553. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  62. Zhang, C.C.; Lodish, H.F. Cytokines regulating hematopoietic stem cell function. Curr. Opin. Hematol. 2008, 15, 307–311. [Google Scholar] [CrossRef] [PubMed]
  63. Zhang, Y.; Gao, S.; Xia, J.; Liu, F. Hematopoietic Hierarchy – An Updated Roadmap. Trends Cell Boil. 2018, 28, 976–986. [Google Scholar] [CrossRef] [PubMed]
  64. Orkin, S.H.; Zon, L.I. Hematopoiesis: An Evolving Paradigm for Stem Cell Biology. Cell 2008, 132, 631–644. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Rieger, M.A.; Schroeder, T. Hematopoiesis. Cold Spring Harb. Perspect. Biol. 2012, 4, a008250. [Google Scholar] [CrossRef]
  66. Schofield, R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978, 4, 7–25. [Google Scholar]
  67. Agas, D.; Marchetti, L.; Douni, E.; Sabbieti, M.G. The unbearable lightness of bone marrow homeostasis. Cytokine Growth Factor Rev. 2015, 26, 347–359. [Google Scholar] [CrossRef]
  68. Scadden, D.T. Nice neighborhood: Emerging concepts of the stem cell niche. Cell 2014, 157, 41–50. [Google Scholar] [CrossRef] [Green Version]
  69. Kopp, H.-G.; Avecilla, S.T.; Hooper, A.T.; Rafii, S. The Bone Marrow Vascular Niche: Home of HSC Differentiation and Mobilization. Physiology 2005, 20, 349–356. [Google Scholar] [CrossRef] [Green Version]
  70. Morrison, S.J.; Scadden, D.T. The bone marrow niche for haematopoietic stem cells. Nature 2014, 505, 327–334. [Google Scholar] [CrossRef] [Green Version]
  71. Kumar, R.; Godavarthy, P.S.; Krause, D.S. The bone marrow microenvironment in health and disease at a glance. J. Cell Sci. 2018, 131, jcs201707. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Naveiras, O.; Nardi, V.; Wenzel, P.L.; Hauschka, P.V.; Fahey, F.; Daley, G.Q. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 2009, 460, 259–263. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Sugimura, R.; Li, L. Shifting in Balance between Osteogenesis and Adipogenesis Substantially Influences Hematopoiesis. J. Mol. Cell Boil. 2009, 2, 61–62. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Rude, R.K.; Gruber, H.E. Magnesium deficiency and osteoporosis: Animal and human observations. J. Nutr. Biochem. 2004, 15, 710–716. [Google Scholar] [CrossRef]
  75. Castiglioni, S.; Cazzaniga, A.; Albisetti, W.; Maier, J.A.M. Magnesium and Osteoporosis: Current State of Knowledge and Future Research Directions. Nutrients 2013, 5, 3022–3033. [Google Scholar] [CrossRef] [Green Version]
  76. Castiglioni, S.; Romeo, V.; Locatelli, L.; Cazzaniga, A.; Maier, J.A. TRPM7 and MagT1 in the osteogenic differentiation of human mesenchymal stem cells in vitro. Sci. Rep. 2018, 8, 16195. [Google Scholar] [CrossRef]
  77. Castiglioni, S.; Romeo, V.; Locatelli, L.; Zocchi, M.; Zecchini, S.; Maier, J.A. The simultaneous downregulation of TRPM7 and MagT1 in human mesenchymal stem cells in vitro: Effects on growth and osteogenic differentiation. Biochem. Biophys. Res. Commun. 2019, 513, 159–165. [Google Scholar] [CrossRef]
  78. Gruber, H.; Rude, R.K.; Wei, L.; Frausto, A.; Mills, B.G.; Norton, H.J. Magnesium deficiency: Effect on bone mineral density in the mouse appendicular skeleton. BMC Musculoskelet. Disord. 2003, 4, 7. [Google Scholar] [CrossRef] [Green Version]
  79. Rude, R.K.; Gruber, H.E.; Wei, L.; Frausto, A. Immunolocalization of RANKL is Increased and OPG Decreased during Dietary Magnesium Deficiency in the Rat. Nutr. Metab. 2005, 2, 24. [Google Scholar] [CrossRef] [Green Version]
  80. Verma, S.; Rajaratnam, J.H.; Denton, J.; A Hoyland, J.; Byers, R. Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J. Clin. Pathol. 2002, 55, 693–698. [Google Scholar] [CrossRef]
  81. Justesen, J.; Stenderup, K.; Ebbesen, E.; Mosekilde, L.; Steiniche, T.; Kassem, M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2001, 2, 165–171. [Google Scholar] [CrossRef] [PubMed]
  82. Beekman, K.M.; Veldhuis-Vlug, A.G.; Heijer, M.D.; Maas, M.; Oleksik, A.; Tanck, M.W.; Ott, S.M.; Hof, R.J.V. ‘T; Lips, P.; Bisschop, P.H.; et al. The effect of raloxifene on bone marrow adipose tissue and bone turnover in postmenopausal women with osteoporosis. Bone 2019, 118, 62–68. [Google Scholar] [CrossRef] [PubMed]
  83. Schwartz, A.V.; Sigurdsson, S.; Hue, T.F.; Lang, T.F.; Harris, T.B.; Rosen, C.J.; Vittinghoff, E.; Siggeirsdottir, K.; Sigurdsson, G.; Oskarsdottir, D.; et al. Vertebral Bone Marrow Fat Associated With Lower Trabecular BMD and Prevalent Vertebral Fracture in Older Adults. J. Clin. Endocrinol. Metab. 2013, 98, 2294–2300. [Google Scholar] [CrossRef] [PubMed]
  84. Lin, C.; Li, N.; Cheng, H.; Yen, M.-L. Oxidative stress induces imbalance of adipogenic/osteoblastic lineage commitment in mesenchymal stem cells through decreasing SIRT1 functions. J. Cell. Mol. Med. 2017, 22, 786–796. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Petrault, I.; Zimowska, W.; Mathieu, J.; Bayle, D.; Rock, E.; Favier, A.; Rayssiguier, Y.; Mazur, A. Changes in gene expression in rat thymocytes identified by cDNA array support the occurrence of oxidative stress in early magnesium deficiency. Biochim. Biophys. Acta 2002, 1586, 92–98. [Google Scholar] [CrossRef] [Green Version]
  86. Malpuech-Brugère, C.; Nowacki, W.; Gueux, E.; Kuryszko, J.; Rock, E.; Rayssiguier, Y.; Mazur, A. Accelerated thymus involution in magnesium-deficient rats is related to enhanced apoptosis and sensitivity to oxidative stress. Br. J. Nutr. 1999, 81, 405–411. [Google Scholar] [CrossRef] [Green Version]
  87. Yang, Y.; Wu, Z.; Chen, Y.; Qiao, J.; Gao, M.; Yuan, J.; Nie, W.; Guo, Y. Magnesium Deficiency Enhances Hydrogen Peroxide Production and Oxidative Damage in Chick Embryo Hepatocyte In Vitro. BioMetals 2006, 19, 71–81. [Google Scholar] [CrossRef]
  88. Leidi, M.; Dellera, F.; Mariotti, M.; Banfi, G.; Crapanzano, C.; Albisetti, W.; Maier, J.A. Nitric oxide mediates low magnesium inhibition of osteoblast-like cell proliferation. J. Nutr. Biochem. 2012, 23, 1224–1229. [Google Scholar] [CrossRef]
  89. Rock, E.; Astier, C.; Lab, C.; Malpuech, C.; Nowacki, W.; Gueux, E.; Mazur, A.; Rayssiguier, Y. Magnesium deficiency in rats induces a rise in plasma nitric oxide. Magnes. Res. 1995, 8, 237–242. [Google Scholar]
  90. Cunha, M.C.R.; Lima, F.D.S.; Vinolo, M.A.R.; Hastreiter, A.; Curi, R.; Borelli, P.; Fock, R.A. Protein Malnutrition Induces Bone Marrow Mesenchymal Stem Cells Commitment to Adipogenic Differentiation Leading to Hematopoietic Failure. PLoS ONE 2013, 8, e58872. [Google Scholar] [CrossRef] [Green Version]
  91. Wilson, A.; Fu, H.; Schiffrin, M.; Winkler, C.; Koufany, M.; Jouzeau, J.-Y.; Bonnet, N.; Gilardi, F.; Renevey, F.; Luther, S.A.; et al. Lack of Adipocytes Alters Hematopoiesis in Lipodystrophic Mice. Front. Immunol. 2018, 9, 2573. [Google Scholar] [CrossRef] [PubMed]
  92. Zhou, B.O.; Yu, H.; Yue, R.; Zhao, Z.; Rios, J.J.; Naveiras, O.; Morrison, S.J. Bone marrow adipocytes promote the regeneration of stem cells and haematopoiesis by secreting SCF. Nature 2017, 19, 891–903. [Google Scholar] [CrossRef]
  93. Xu, Y.; Takahashi, Y.; Wang, Y.; Hama, A.; Nishio, N.; Muramatsu, H.; Tanaka, M.; Yoshida, N.; Villalobos, I.B.; Yagasaki, H.; et al. Downregulation of GATA-2 and overexpression of adipogenic gene-PPARγ in mesenchymal stem cells from patients with aplastic anemia. Exp. Hematol. 2009, 37, 1393–1399. [Google Scholar] [CrossRef] [PubMed]
  94. Liu, H.; He, J.; Koh, S.P.; Zhong, Y.; Liu, Z.; Wang, Z.; Zhang, Y.; Li, Z.; Tam, B.T.; Lin, P.; et al. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci. Transl. Med. 2019, 11, eaau9087. [Google Scholar] [CrossRef] [PubMed]
  95. Nombela-Arrieta, C.; Pivarnik, G.; Winkel, B.; Canty, K.J.; Harley, B.; Mahoney, J.E.; Park, S.-Y.; Lu, J.; Protopopov, A.; Silberstein, L.E. Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment. Nat. Cell Biol. 2013, 15, 533–543. [Google Scholar] [CrossRef]
  96. Filipowska, J.; Tomaszewski, K.A.; Niedźwiedzki, Ł.; Walocha, J.A.; Niedźwiedzki, T. The role of vasculature in bone development, regeneration and proper systemic functioning. Angiogenesis 2017, 20, 291–302. [Google Scholar] [CrossRef] [Green Version]
  97. Kiel, M.J.; Yilmaz, Ö.H.; Iwashita, T.; Yilmaz, O.H.; Terhorst, C.; Morrison, S.J. SLAM Family Receptors Distinguish Hematopoietic Stem and Progenitor Cells and Reveal Endothelial Niches for Stem Cells. Cell 2005, 121, 1109–1121. [Google Scholar] [CrossRef] [Green Version]
  98. Ding, L.; Saunders, T.L.; Enikolopov, G.; Morrison, S.J. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 2012, 481, 457–462. [Google Scholar] [CrossRef] [Green Version]
  99. Butler, J.M.; Nolan, D.J.; Vertes, E.L.; Varnum-Finney, B.; Kobayashi, H.; Hooper, A.T.; Seandel, M.; Shido, K.; White, I.A.; Kobayashi, M.; et al. Endothelial Cells Are Essential for the Self-Renewal and Repopulation of Notch-Dependent Hematopoietic Stem Cells. Cell Stem Cell 2010, 6, 251–264. [Google Scholar] [CrossRef] [Green Version]
  100. Poulos, M.G.; Guo, P.; Kofler, N.M.; Pinho, S.; Gutkin, M.C.; Tikhonova, A.; Aifantis, I.; Frenette, P.S.; Kitajewski, J.; Rafii, S.; et al. Endothelial Jagged-1 Is Necessary for Homeostatic and Regenerative Hematopoiesis. Cell Rep. 2013, 4, 1022–1034. [Google Scholar] [CrossRef] [Green Version]
  101. Shahrabi, S.; Rezaeeyan, H.; Ahmadzadeh, A.; Shahjahani, M.; Saki, N. Bone marrow blood vessels: Normal and neoplastic niche. Oncol. Rev. 2016, 10, 306. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  102. Itkin, T.; Gur-Cohen, S.; Spencer, J.A.; Schajnovitz, A.; Ramasamy, S.; Kusumbe, A.P.; Ledergor, G.; Jung, Y.; Milo, I.; Poulos, M.G.; et al. Distinct bone marrow blood vessels differentially regulate haematopoiesis. Nature 2016, 532, 323–328. [Google Scholar] [CrossRef]
  103. Maier, J.A. Endothelial cells and magnesium: Implications in atherosclerosis. Clin. Sci. 2011, 122, 397–407. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  104. Maier, J.A.; Malpuech-Brugère, C.; Zimowska, W.; Rayssiguier, Y.; Mazur, A. Low magnesium promotes endothelial cell dysfunction: Implications for atherosclerosis, inflammation and thrombosis. Biochim. Biophys. Acta 2004, 1689, 13–21. [Google Scholar] [CrossRef] [PubMed]
  105. Baldoli, E.; Castiglioni, S.; Maier, J.A. Regulation and Function of TRPM7 in Human Endothelial Cells: TRPM7 as a Potential Novel Regulator of Endothelial Function. PLoS ONE 2013, 8, e59891. [Google Scholar] [CrossRef] [Green Version]
  106. Mofrad, M.D.; Djafarian, K.; Mozaffari, H.; Shab-Bidar, S. Effect of magnesium supplementation on endothelial function: A systematic review and meta-analysis of randomized controlled trials. Atherosclerosis 2018, 273, 98–105. [Google Scholar] [CrossRef]
  107. Winkler, I.G.; Sims, N.A.; Pettit, A.R.; Barbier, V.; Nowlan, B.; Helwani, F.; Poulton, I.J.; van Rooijen, N.; Alexander, K.A.; Raggatt, L.J.; et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 2010, 116, 4815–4828. [Google Scholar] [CrossRef] [Green Version]
  108. McCabe, A.; MacNamara, K.C. Macrophages: Key regulators of steady-state and demand-adapted hematopoiesis. Exp. Hematol. 2016, 44, 213–222. [Google Scholar] [CrossRef] [Green Version]
  109. Chow, A.; Lucas, D.; Hidalgo, A.; Méndez-Ferrer, S.; Hashimoto, D.; Scheiermann, C.; Battista, M.; Leboeuf, M.; Prophete, C.; van Rooijen, N.; et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J. Exp. Med. 2011, 208, 261–271. [Google Scholar] [CrossRef]
  110. Chasis, J.A.; Mohandas, N. Erythroblastic islands: Niches for erythropoiesis. Blood 2008, 112, 470–478. [Google Scholar] [CrossRef] [Green Version]
  111. Li, D.; Xue, W.; Li, M.; Dong, M.; Wang, J.; Wang, X.; Li, X.; Chen, K.; Zhang, W.; Wu, S.; et al. VCAM-1+ macrophages guide the homing of HSPCs to a vascular niche. Nature 2018, 564, 119–124. [Google Scholar] [CrossRef] [PubMed]
  112. Cavaillon, J.M. Cytokines and macrophages. Biomed. Pharmacother. 1994, 48, 445–453. [Google Scholar] [CrossRef]
  113. Metcalf, D. Hematopoietic cytokines. Blood 2008, 111, 485–491. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  114. Libako, P.; Nowacki, W.; Castiglioni, S.; Mazur, A.; Maier, J.A. Extracellular magnesium and calcium blockers modulate macrophage activity. Magnes. Res. 2016, 29, 11–21. [Google Scholar] [CrossRef]
  115. Tam, M.; Gomez, S.; González-Gross, M.; Marcos, A. Possible roles of magnesium on the immune system. Eur. J. Clin. Nutr. 2003, 57, 1193–1197. [Google Scholar] [CrossRef] [Green Version]
  116. Weglicki, W.B.; Phillips, T.M. Pathobiology of magnesium deficiency: A cytokine/neurogenic inflammation hypothesis. Am. J. Physiol. Integr. Comp. Physiol. 1992, 263, R734–R737. [Google Scholar] [CrossRef] [Green Version]
  117. Mazur, A.; Maier, J.A.; Rock, E.; Gueux, E.; Nowacki, W.; Rayssiguier, Y. Magnesium and the inflammatory response: Potential physiopathological implications. Arch. Biochem. Biophys. 2007, 458, 48–56. [Google Scholar] [CrossRef]
  118. Yokoyama, T.; Oono, H.; Miyamoto, A.; Ishiguro, S.; Nishio, A. Magnesium-deficient medium enhances NO production in alveolar macrophages isolated from rats. Life Sci. 2003, 72, 1247–1257. [Google Scholar] [CrossRef]
  119. Shigematsu, M.; Tomonaga, S.; Shimokawa, F.; Murakami, M.; Imamura, T.; Matsui, T.; Funaba, M. Regulatory responses of hepatocytes, macrophages and vascular endothelial cells to magnesium deficiency. J. Nutr. Biochem. 2018, 56, 35–47. [Google Scholar] [CrossRef]
  120. Hu, T.; Xu, H.; Wang, C.; Qin, H.; An, Z. Magnesium enhances the chondrogenic differentiation of mesenchymal stem cells by inhibiting activated macrophage-induced inflammation. Sci. Rep. 2018, 8, 3406. [Google Scholar] [CrossRef]
  121. Su, N.-Y.; Peng, T.-C.; Tsai, P.-S.; Huang, C.-J. Phosphoinositide 3-kinase/Akt pathway is involved in mediating the anti-inflammation effects of magnesium sulfate. J. Surg. Res. 2013, 185, 726–732. [Google Scholar] [CrossRef] [PubMed]
  122. Sun, L.; Li, X.; Xu, M.; Yang, F.; Wang, W.; Niu, X. In vitro immunomodulation of magnesium on monocytic cell toward anti-inflammatory macrophages. Regen. Biomater. 2020, 7, 391–401. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  123. Li, B.; Cao, H.; Zhao, Y.; Cheng, M.; Qin, H.; Cheng, T.; Hu, Y.; Zhang, X.; Liu, X. In vitro and in vivo responses of macrophages to magnesium-doped titanium. Sci. Rep. 2017, 7, 42707. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  124. Yamashita, M.; Passegué, E. TNF-α Coordinates Hematopoietic Stem Cell Survival and Myeloid Regeneration. Cell Stem Cell 2019, 25, 357–372. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  125. Pietras, E.M.; Mirantes-Barbeito, C.; Fong, S.L.; Loeffler, D.; Kovtonyuk, L.V.; Zhang, S.; Lakshminarasimhan, R.; Chin, C.P.; Techner, J.-M.; Will, B.; et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nature 2016, 18, 607–618. [Google Scholar] [CrossRef]
  126. Barminko, J.; Reinholt, B.; Baron, M.H. Development and differentiation of the erythroid lineage in mammals. Dev. Comp. Immunol. 2016, 58, 18–29. [Google Scholar] [CrossRef] [Green Version]
  127. Comazzetto, S.; Murphy, M.M.; Berto, S.; Jeffery, E.; Zhao, Z.; Morrison, S.J. Restricted Hematopoietic Progenitors and Erythropoiesis Require SCF from Leptin Receptor+ Niche Cells in the Bone Marrow. Cell Stem Cell 2019, 24, 477–486. [Google Scholar] [CrossRef] [Green Version]
  128. Mello, F.V.; Land, M.G.P.; Costa, E.S.; Teodósio, C.; Sanchez, M.-L.; Bárcena, P.; Peres, R.T.; Pedreira, C.E.; Alves, L.R.; Orfao, A. Maturation-associated gene expression profiles during normal human bone marrow erythropoiesis. Cell Death Discov. 2019, 5, 69. [Google Scholar] [CrossRef] [Green Version]
  129. Eggold, J.T.; Rankin, E.B. Erythropoiesis, EPO, macrophages, and bone. Bone 2019, 119, 36–41. [Google Scholar] [CrossRef]
  130. Giger, K.M.; Kalfa, T.A. Phylogenetic and Ontogenetic View of Erythroblastic Islands. Biomed. Res. Int. 2015, 2015, 873628. [Google Scholar] [CrossRef] [Green Version]
  131. Koury, M.J.; Ponka, P. New insights into erythropoiesis: The roles of folate, vitamin B12, and iron. Annu Rev. Nutr. 2004, 24, 105–131. [Google Scholar] [CrossRef] [PubMed]
  132. Bang, O.; Orskov, S.L. The magnesium content of the erythrocytes in pernicious and some other anemias. J. Clin. Investig. 1939, 18, 497–500. [Google Scholar] [CrossRef] [Green Version]
  133. Cohlan, S.Q.; Jansen, V.; Dancis, J.; Piomelli, S. Microcytic anemia with erythroblastosis in offspring of magnesium-deprived rats. Blood 1970, 36, 500–506. [Google Scholar] [CrossRef] [PubMed]
  134. Piomelli, S.; Jansen, V.; Dancis, J. The hemolytic anemia of magnesium deficiency in adult rats. Blood. 1973, 41, 451–459. [Google Scholar] [CrossRef] [PubMed]
  135. Cosens, G.; Diamond, I.; Theriault, L.L.; Hurley, L.S. Magnesium deficiency anemia in the rat fetus. Pediatr. Res. 1977, 11, 758–764. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  136. Keen, C.L.; Lowney, P.; Gershwin, M.E.; Hurley, L.S.; Stern, J.S. Dietary magnesium intake influences exercise capacity and hematologic parameters in rats. Metabolism 1987, 36, 788–793. [Google Scholar] [CrossRef]
  137. De Franceschi, L.; Beuzard, Y.; Jouault, H.; Brugnara, C. Modulation of erythrocyte potassium chloride cotransport, potassium content, and density by dietary magnesium intake in transgenic SAD mouse. Blood 1996, 88, 2738–2744. [Google Scholar] [CrossRef]
  138. Mak, I.T.; Stafford, R.; Weglicki, W.B. Loss of red blood cell glutathione during Mg deficiency: Prevention by vitamin, E.; D-propranolol, and chloroquine. Am. J. Physiol. 1994, 267 Pt 1, C1366–C1370. [Google Scholar] [CrossRef]
  139. Mak, I.T.; Komarov, A.M.; Wagner, T.L.; Stafford, R.E.; Dickens, B.F.; Weglicki, W.B. Enhanced NO production during Mg deficiency and its role in mediating red blood cell glutathione loss. Am. J. Physiol. 1996, 271 Pt 1, C385–C390. [Google Scholar] [CrossRef]
  140. Schauf, B.; Mannschreck, B.; Becker, S.; Dietz, K.; Wallwiener, D.; Aydeniz, B. Evaluation of red blood cell deformability and uterine blood flow in pregnant women with preeclampsia or iugr and reduced uterine blood flow following the intravenous application of magnesium. Hypertens. Pregnancy 2004, 23, 331–343. [Google Scholar] [CrossRef]
  141. Schauf, B.; Becker, S.; Abele, H.; Klever, T.; Wallwiener, D.; Aydeniz, B. Effect of magnesium on red blood cell deformability in pregnancy. Hypertens. Pregnancy 2005, 24, 17–27. [Google Scholar] [CrossRef] [PubMed]
  142. Xu, X.; Hall, J.; Byles, J.; Shi, Z. Dietary pattern, serum magnesium, ferritin, C-reactive protein and anaemia among older people. Clin Nutr. 2017, 36, 444–451. [Google Scholar] [CrossRef] [PubMed]
  143. Jelkmann, W. Regulation of erythropoietin production. J. Physiol. 2011, 589 Pt 6, 1251–1258. [Google Scholar] [CrossRef]
  144. Yu, L.; Song, J.; Lu, X.; Zu, Y.; Li, H.; Wang, S. Association between Serum Magnesium and Erythropoietin Responsiveness in Hemodialysis Patients: A Cross-Sectional Study. Kidney Blood Press Res. 2019, 44, 354–361. [Google Scholar] [CrossRef]
  145. Torii, S.; Kobayashi, K.; Takahashi, M.; Katahira, K.; Goryo, K.; Matsushita, N.; Yasumoto, K.-I.; Fujii-Kuriyama, Y.; Sogawa, K. Magnesium deficiency causes loss of response to intermittent hypoxia in paraganglion cells. J. Biol. Chem. 2009, 284, 19077–19089. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  146. Haase, V.H. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 2013, 27, 41–53. [Google Scholar] [CrossRef] [PubMed]
  147. Takemoto, S.; Yamamoto, A.; Tomonaga, S.; Funaba, M.; Matsui, T. Magnesium deficiency induces the emergence of mast cells in the liver of rats. J. Nutr. Sci. Vitaminol. 2013, 59, 560–563. [Google Scholar] [CrossRef] [Green Version]
  148. Kurantsin-Mills, J.; Cassidy, M.M.; Stafford, R.E.; Weglicki, W.B. Marked alterations in circulating inflammatory cells during cardiomyopathy development in a magnesium-deficient rat model. Br. J. Nutr. 1997, 78, 845–855. [Google Scholar] [CrossRef] [Green Version]
  149. Kennedy, A.D.; DeLeo, F.R. Neutrophil apoptosis and the resolution of infection. Immunol. Res. 2009, 43, 25–61. [Google Scholar] [CrossRef]
  150. Manz, M.G.; Boettcher, S. Emergency granulopoiesis. Nat. Rev. Immunol. 2014, 14, 302–314. [Google Scholar] [CrossRef]
  151. Panopoulos, A.D.; Zhang, L.; Snow, J.W.; Jones, D.M.; Smith, A.M.; El Kasmi, K.C.; Liu, F.; Goldsmith, M.A.; Link, D.C.; Murray, P.J.; et al. STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. Blood 2006, 108, 3682–3690. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  152. Yvan-Charvet, L.; Ng, L.G. Granulopoiesis and Neutrophil Homeostasis: A Metabolic, Daily Balancing Act. Trends Immunol. 2019, 40, 598–612. [Google Scholar] [CrossRef] [PubMed]
  153. De Filippo, K.; Rankin, S.M. CXCR4, the master regulator of neutrophil trafficking in homeostasis and disease. Eur. J. Clin. Investig. 2018, 48 (Suppl. 2), e12949. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  154. Nauseef, W.M.; Borregaard, N. Neutrophils at work. Nat. Immunol. 2014, 15, 602–611. [Google Scholar] [CrossRef]
  155. Rijkers, G.T.; Griffioen, A.W. Changes in free cytoplasmic magnesium following activation of human lymphocytes. Biochem. J. 1993, 289, 373–377. [Google Scholar] [CrossRef]
  156. Brandao, K.; Deason-Towne, F.; Perraud, A.L.; Schmitz, C. The role of Mg2+ in immune cells. Immunol. Res. 2013, 55, 261–269. [Google Scholar] [CrossRef]
  157. Hass, G.M.; Laing, G.H.; Galt, R.M.; McCreary, P.A. Recent Advances: Immunopathology of Magnesium Deficiency in Rats. Induction of Tumors; Incidence, Transmission and Prevention of Lymphoma-Leukemia. Magnes. Bull. 1981, 3, 217–228. [Google Scholar]
  158. Jasmin, G. Thymic lymphosarcoma in magnesium-deficient rats. Biol. Trace Elem. Res. 1979, 1, 217–228. [Google Scholar] [CrossRef]
  159. Averdunk, R.; Bippus, P.H.; Günther, T.; Merker, H.J. Development and properties of malignant lymphoma induced by magnesium deficiency in rats. J. Cancer Res. Clin. Oncol. 1982, 104, 63–73. [Google Scholar] [CrossRef]
  160. BOIS, P. Tumour of the thymus in magnesium-deficient rats. Nature 1964, 204, 1316. [Google Scholar] [CrossRef]
  161. Sahin, G.; Ertem, U.; Duru, F.; Birgen, D.; Yüksek, N. High prevelance of chronic magnesium deficiency in T cell lymphoblastic leukemia and chronic zinc deficiency in children with acute lymphoblastic leukemia and malignant lymphoma. Leuk. Lymphoma 2000, 39, 555–562. [Google Scholar] [CrossRef] [PubMed]
  162. Merza, W.M.; majid, A.Y.; Daoud, M.S.; Jawad, A.M. Serum Magnesium Concentration in Patients with Leukemia and Lymphoma. Fac. Med. Baghdad. 2009, 51, 101. [Google Scholar]
  163. Guo, C.Y.; Halton, J.M.; Barr, R.D.; Atkinson, S.A. Hypomagnesemia associated with chemotherapy in patients treated for acute lymphoblastic leukemia: Possible mechanisms. Oncol. Rep. 2004, 11, 185–189. [Google Scholar] [CrossRef] [PubMed]
  164. Afridi, H.I.; Kazi, T.G.; Talpur, F.N. Correlation of Calcium and Magnesium Levels in the Biological Samples of Different Types of Acute Leukemia Children. Biol. Trace Elem. Res. 2018, 186, 395–406. [Google Scholar] [CrossRef]
  165. Feske, S.; Skolnik, E.Y.; Prakriya, M. Ion channels and transporters in lymphocyte function and immunity. Nat. Rev. Immunol. 2012, 12, 532–547. [Google Scholar] [CrossRef] [Green Version]
  166. Sahni, J.; Scharenberg, A.M. TRPM7 ion channels are required for sustained phosphoinositide 3-kinase signaling in lymphocytes. Cell Metab. 2008, 8, 84–93. [Google Scholar] [CrossRef] [Green Version]
  167. Krishnamoorthy, M.; Buhari, F.H.M.; Zhao, T.; Brauer, P.M.; Burrows, K.; Cao, E.Y.; Moxley-Paquette, V.; Mortha, A.; Zúñiga-Pflücker, J.C.; Treanor, B. The ion channel TRPM7 is required for B cell lymphopoiesis. Sci. Signal. 2018, 11, eaan2693. [Google Scholar] [CrossRef] [Green Version]
  168. Li, F.Y.; Chaigne-Delalande, B.; Su, H.; Uzel, G.; Matthews, H.; Lenardo, M.J. XMEN disease: A new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood 2014, 123, 2148–2152. [Google Scholar] [CrossRef] [Green Version]
  169. Ravell, J.C.; Matsuda-Lennikov, M.; Chauvin, S.D.; Zou, J.; Biancalana, M.; Deeb, S.J.; Price, S.; Su, H.C.; Notarangelo, G.; Jiang, P.; et al. Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease. J. Clin. Investig. 2020, 130, 507–522. [Google Scholar] [CrossRef] [Green Version]
  170. Blommaert, E.; Péanne, R.; Cherepanova, N.A.; Rymen, D.; Staels, F.; Jaeken, J.; Race, V.; Keldermans, L.; Souche, E.; Corveleyn, A.; et al. Mutations in MAGT1 lead to a glycosylation disorder with a variable phenotype. Proc. Natl. Acad. Sci. USA 2019, 116, 9865–9870. [Google Scholar] [CrossRef] [Green Version]
  171. Ravell, J.C.; Chauvin, S.D.; He, T.; Lenardo, M. An Update on XMEN Disease. J. Clin. Immunol. 2020, 40, 671–681. [Google Scholar] [CrossRef] [PubMed]
  172. Matsuda-Lennikov, M.; Biancalana, M.; Zou, J.; Ravell, J.C.; Zheng, L.; Kanellopoulou, C.; Jiang, P.; Notarangelo, G.; Jing, H.; Masutani, E.; et al. Magnesium transporter 1 (MAGT1) deficiency causes selective defects in N-linked glycosylation and expression of immune-response genes. J. Boil. Chem. 2019, 294, 13638–13656. [Google Scholar] [CrossRef] [PubMed]
  173. Chaigne-Delalande, B.; Li, F.-Y.; O’Connor, G.M.; Lukacs, M.J.; Jiang, P.; Zheng, L.; Shatzer, A.; Biancalana, M.; Pittaluga, S.; Matthews, H.F.; et al. Mg2+ Regulates Cytotoxic Functions of NK and CD8 T Cells in Chronic EBV Infection Through NKG2D. Science 2013, 341, 186–191. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  174. Shechter, M.; Merz, N.B.; Rude, R.K.; Labrador, M.J.P.; Meisel, S.R.; Shah, P.K.; Kaul, S. Low intracellular magnesium levels promote platelet-dependent thrombosis in patients with coronary artery disease. Am. Heart J. 2000, 140, 212–218. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  175. Ravn, H.B.; Kristensen, S.D.; Vissinger, H.; Husted, S.E. Magnesium inhibits human platelets. Blood Coagul. Fibrinolysis 1996, 7, 241–244. [Google Scholar] [CrossRef]
  176. Nadler, J.L.; Malayan, S.; Luong, H.; Shaw, S.; Natarajan, R.D.; Rude, R.K. Intracellular free magnesium deficiency plays a key role in increased platelet reactivity in type II diabetes mellitus. Diabetes Care 1992, 15, 835–841. [Google Scholar] [CrossRef]
  177. Takaya, J.; Yamato, F.; Higashino, H.; Kobayashi, Y. Relationship of intracellular magnesium of cord blood platelets to birth weight. Metabolism 2004, 53, 1544–1547. [Google Scholar] [CrossRef]
  178. Oliveira, D.C.; Nogueira-Pedro, A.; Santos, E.W.; Hastreiter, A.; Silva, G.B.; Borelli, P.; Fock, R.A. A review of select minerals influencing the haematopoietic process. Nutr. Res. Rev. 2018, 31, 267–280. [Google Scholar] [CrossRef]
Figure 1. On the hematopoietic cell surface, transient receptor potential cation channel subfamily M member 7 (TRPM7) and magnesium transporter 1(MagT1) facilitate magnesium influx into the cell. In the cytoplasm, the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway is magnesium-sensitive, and the activation of this signaling cascade induces cell growth, proliferation, and the inhibition of autophagy. Additionally, increased Mg2+ concentration is able to decrease proinflammatory cytokine production, by inhibiting the nuclear translocation and phosphorylation of nuclear factor kappa B (NF-κB) and rise in basal inhibitor of NF-κB (IĸBα) levels, downregulating tumor necrosis factor alpha (TNF-α) and interleukin (IL)-1β release, and reducing ROS production. Solid black arrows indicate the pathway activated, while dot black arrows indicate the pathways inhibited. Red arrows pointing down indicates reduction, while blue arrows pointing up indicates increase.
Figure 1. On the hematopoietic cell surface, transient receptor potential cation channel subfamily M member 7 (TRPM7) and magnesium transporter 1(MagT1) facilitate magnesium influx into the cell. In the cytoplasm, the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway is magnesium-sensitive, and the activation of this signaling cascade induces cell growth, proliferation, and the inhibition of autophagy. Additionally, increased Mg2+ concentration is able to decrease proinflammatory cytokine production, by inhibiting the nuclear translocation and phosphorylation of nuclear factor kappa B (NF-κB) and rise in basal inhibitor of NF-κB (IĸBα) levels, downregulating tumor necrosis factor alpha (TNF-α) and interleukin (IL)-1β release, and reducing ROS production. Solid black arrows indicate the pathway activated, while dot black arrows indicate the pathways inhibited. Red arrows pointing down indicates reduction, while blue arrows pointing up indicates increase.
Ijms 21 07084 g001
Table 1. Main findings of relationships between Mg2+ and hematopoietic tissue.
Table 1. Main findings of relationships between Mg2+ and hematopoietic tissue.
ReferenceMain FindingsSource
Mesenchymal Stem Cells and Osteoblasts
[31]Increase in Mg2+ enhanced expression of RUNX2, OSTERIX, and OSTEOCALCIN genes, increased the levels cyclin D1 and PCNA proteins, and induced the activation of Notch signaling.BMSCs
[32]Higher Mg2+ concentration led to upregulation of RUNX2, BMP2, ALP, OPN, and ColI and increased PI3K/Akt signaling pathway.Osteoblasts from animal model
[33]Higher Mg2+ levels triggered PI3K phosphorylation via TRPM7 and led to migration of osteoblasts.hFOB1.19 (human osteoblast cells)
[34]Increase in Mg2+ led to changes in the expression of TRPM7 and in homeostasis of other important metal ions for bone tissue, inhibiting ALP activity in osteoblasts.SaOS-2 cells and human osteoblasts
[35]Decreased osteoblast number.Bone marrow from mice
Endothelial Cells
[36]Lower Mg2+ levels impaired proliferation and migration, and increased IL-6, NOS activity, and VCAM expression.1G11 cells
[37]Mg2+ deficiency triggered higher NF-ĸB activation, and increased IL-8, RANTES, and GM-CSF.HUVEC cells
[38]Lower Mg2+ concentration decreased proliferation taxa and downregulation of TRPM7.HMEC cells
[39]Mg2+ deficiency increased ROS, PGE2, TNFα, and IL-1β levels, triggered changes in mRNA of ICAM-1 and VCAM-1, decreased viability and cell proliferation, triggered changes in the endothelial permeability, and influenced integrity of the endothelial barrier through the S1P1–Rac1 pathway.ECs from animal model
[40]Mg2+ supplementation improved endothelial function.Clinical trial
[41]Daily Mg2+ supplement of 350 mg for 24 weeks led to no improvement in soluble vascular cell adhesion molecule (sVCAM)-1, soluble intercellular adhesion molecule (sICAM)-1, and soluble endothelial selectin (sE-selectin), along with no change in FMD markers of endothelial function or inflammatory parameters.Clinical trial
Macrophages
[42]Mg2+ deficiency increased TNF-α and IL-1 mRNA levels with the involvement of Ca2+ signaling pathways.Rat alveolar macrophages
[43]Low Mg2+ concentration increased NF-κB activity and changed HMGB1 expression.RAW264.7 cells
[44]Increased Mg2+ concentration inhibited the nuclear translocation and phosphorylation of NF-κB and led to a rise in basal IĸBα levels.Human PBMCs
Erythropoiesis
[45]Mg2+ deficiency decreased plasma level, and led to faster aging of RBCs, as well as reticulocytosis.Animal model
[46]Mg2+ deficiency increased Fe absorption and concentration, but reduced the number of RBCs.Animal model
[47]Inverse association between Mg2+ intake and anemia.Cross-sectional study
[48]Association between increased serum Mg2+ and decreased risk of anemia in women, dependent on ferritin levels.Cross-sectional study
[49]Decreased levels of serum ferritin and Mg2+ were associated with anemia in pregnant women.Cross-sectional study
[50]Mg2+ supplementation raised the hemoglobin levels and counts of erythrocytes.Clinical trial
Granulopoiesis
[51]Boost in circulating eosinophils during Mg2+ deficiency.Experimental model
[52]Mg2+ deficiency impaired mast-cell functions.Experimental model
[53]Mg2+ deficiency increased the mast cells in the bone marrow.Experimental model
[54]Increase in the number and activity of PMNs during Mg2+ deficiency.Experimental model
[26]Lower Mg2+ levels triggered granulocytic differentiation and changes in proteins related to cell-cycle control.HL-60 cells
[15]Mg2+ deficiency resulted in hypercellular bone marrow, as well as a greater number of granulocytic cell; one animal also developed leukemia with granulocytic infiltrate in several organs.Experimental model
Thrombopoiesis
[55]Higher serum Mg2+ levels were associated with increased platelet numbers and lower risk of development of thrombocytopenia.Cross-sectional study
[56]Mg2+ deficiency impaired the number and shape of megakaryocytes from bone marrow.Experimental model
[16]Changes in the TRPM7 channel and Mg2+ homeostasis in megakaryocytes triggered macrothrombocytopenia, altering the activity of the NMMIIA and the cytoskeleton, affecting the maturation of platelets in the bone marrow.Experimental model
Abbreviations: RUNX2 (RUNX Family Transcription Factor 2); PCNA (Proliferating Cell Nuclear Antigen); BMP2 (Bone Morphogenetic Protein 2); OPN (Osteoprotegerin); ALP (Alkaline Phosphatase), COL1 (Collagenase I); PI3K ( Phosphoinositide 3-Kinase); Akt (Protein Kinase B); TRPM7 (Transient Receptor Potential Cation Channel Subfamily M Member 7); IL-6 (Interleukin-6); NOS (Nitric Oxide Synthase); VCAM (Vascular Cell Adhesion Molecule); NF-ĸB (Nuclear Factor Kappa B); RANTES (Regulated upon activation, normal T cell expressed and secrete); GM-CSF (Granulocyte Macrophage Colony-Stimulating Factor); ROS (Reactive Oxygen Species), PGE2 ( Prostaglandin E2); TNFα (Tumor Necrosis Factor Alpha); ICAM (Intercellular Adhesion Molecule); HGMB1(High-Mobility Group Box 1); IĸBα (Inhibitor of NF-κB); S1P1 (Sphingosine-1-Phosphate Receptor 1 ); Rac1 (Ras-related C3 Botulinum Toxin Substrate 1); RBCs (Red Blood Cells); PMNs (Polymorphonuclear Cells); NMMIIA (Nonmuscular Myosin Protein IIA).

Share and Cite

MDPI and ACS Style

Lima, F.d.S.; Fock, R.A. A Review of the Action of Magnesium on Several Processes Involved in the Modulation of Hematopoiesis. Int. J. Mol. Sci. 2020, 21, 7084. https://doi.org/10.3390/ijms21197084

AMA Style

Lima FdS, Fock RA. A Review of the Action of Magnesium on Several Processes Involved in the Modulation of Hematopoiesis. International Journal of Molecular Sciences. 2020; 21(19):7084. https://doi.org/10.3390/ijms21197084

Chicago/Turabian Style

Lima, Fabiana da Silva, and Ricardo Ambrósio Fock. 2020. "A Review of the Action of Magnesium on Several Processes Involved in the Modulation of Hematopoiesis" International Journal of Molecular Sciences 21, no. 19: 7084. https://doi.org/10.3390/ijms21197084

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop